NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 421
(Total Views: 278)
Posted On: 07/29/2021 3:51:10 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Study Results Indicating DehydraTECH-CBD Lowers Blood Pressure
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released results from its recent human clinical study focused on evaluating DehydraTECh(TM)-processed cannabidiol (“CBD”) for potential application against hypertension. The study, HYPER-H21-1, indicated a rapid, sustained drop in blood pressure with DehydraTECH-CBD as well as excellent tolerability. The partial results will be followed by more complete results after additional BP subset analyses and other data analyses are completed. According to the study’s lead investigator, Dr. Phil Ainslie, the early results appear to be extremely promising as blood pressure was reduced across both male and female volunteers and supported earlier findings that indicate DehydraTECH delivers superior performance over generic CBD controls. The results show potential for use in the at-risk hypertensive population and provide support for moving forward into more prolonged repeat dosing and longer-term clinical trials. The potential benefits these results show can be surmised by noting that other studies of coronary heart disease (“CHD”) report that lowering systolic pressure by 10 mm Hg or diastolic pressure by 5 mm Hg using any of the main classes of drugs reduced CHD events (fatal and nonfatal) by about a quarter and stroke by about a third, with heart failure also reduced by about 25%. “We are very encouraged by these early results in our 2021 hypertension program,” said Lexaris CEO Chris Bunka. “Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in stage 2 hypertensive volunteers.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released results from its recent human clinical study focused on evaluating DehydraTECh(TM)-processed cannabidiol (“CBD”) for potential application against hypertension. The study, HYPER-H21-1, indicated a rapid, sustained drop in blood pressure with DehydraTECH-CBD as well as excellent tolerability. The partial results will be followed by more complete results after additional BP subset analyses and other data analyses are completed. According to the study’s lead investigator, Dr. Phil Ainslie, the early results appear to be extremely promising as blood pressure was reduced across both male and female volunteers and supported earlier findings that indicate DehydraTECH delivers superior performance over generic CBD controls. The results show potential for use in the at-risk hypertensive population and provide support for moving forward into more prolonged repeat dosing and longer-term clinical trials. The potential benefits these results show can be surmised by noting that other studies of coronary heart disease (“CHD”) report that lowering systolic pressure by 10 mm Hg or diastolic pressure by 5 mm Hg using any of the main classes of drugs reduced CHD events (fatal and nonfatal) by about a quarter and stroke by about a third, with heart failure also reduced by about 25%. “We are very encouraged by these early results in our 2021 hypertension program,” said Lexaris CEO Chris Bunka. “Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in stage 2 hypertensive volunteers.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)